Evidence map›Paper›PMID 29264519›Full record

ArticleJournal of the Endocrine Society2017

WISP1 Is a Marker of Systemic and Adipose Tissue Inflammation in Dysmetabolic Subjects With or Without Type 2 Diabetes.

Ilaria Barchetta, Flavia Agata Cimini, Danila Capoccia, Riccardo De Gioannis, Alessandra Porzia, Fabrizio Mainiero, Michele Di Martino, Laura Bertoccini, Marzia De Bernardinis, Frida Leonetti and 3 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the Endocrine Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Increased Circulating Interleukin Concentrations in Type 2 Diabetes: A Systematic Review and Meta-Analysis.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025
    Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Article
  7. An overview of CCN4 (WISP1) role in human diseases.Journal of translational medicine · 2024
    Review
  8. Review
  9. Article
  10. CCN proteins: opportunities for clinical studies-a personal perspective.Journal of cell communication and signaling · 2023
    Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Ilaria BarchettaDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Flavia Agata CiminiDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Danila CapocciaDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Riccardo De GioannisDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Alessandra PorziaDepartment of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Fabrizio MainieroDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Michele Di MartinoDepartment of Radiological Sciences, Oncology and Pathology, Sapienza University of Rome, 00161 Rome, Italy.
Laura BertocciniDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Marzia De BernardinisDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Frida LeonettiDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Marco Giorgio BaroniDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Andrea LenziDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Maria Gisella CavalloDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Sapienza University of Rome · ITIstituto Neurologico Mediterraneo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextWnt1-inducible signaling pathway protein 1 (WISP1) is a novel adipokine participating in adipose tissue (AT) dysfunction; so far, no data on WISP1 in diabetes are available.

objectivesTo evaluate plasma WISP1 in subjects with type 2 diabetes (T2D) and its correlates linked to AT inflammation. DESIGN AND

participantsFor this cross-sectional study, 97 consecutive dysmetabolic patients were recruited at the diabetes outpatient clinics of Sapienza University in Rome; 71 of them had T2D, with (n = 35) or without (n = 36) obesity, and 26 were obese patients without diabetes. Twenty-one normal-weight nondiabetic individuals were enrolled as a control group. Study participants underwent clinical workup and blood sampling for metabolic/inflammatory characterization; magnetic resonance imaging (MRI) data on subcutaneous AT and visceral AT (VAT) area, hepatic fat content, and VAT homogeneity were available for most diabetic patients.

resultsPlasma WISP1 significantly increased throughout classes of obesity and correlated with greater VAT area, interleukin-8 (IL-8), and lower adiponectin levels, without differing between diabetic and nondiabetic participants. Higher IL-8 was the main determinant of increased WISP1. MRI-assessed VAT inhomogeneity was associated with higher WISP1, IL-8 and C-reactive protein levels, independent of obesity; high WISP1 strongly predicted VAT inhomogeneity (

conclusionsWISP1 levels are increased in obese persons and are directly related to adiposity, independent of glycemic status or insulin resistance; moreover, they are strongly associated with increased plasma IL-8 and signal abnormalities of VAT. The overall data add insights to the mechanisms underlying metabolic alterations and may open a scenario for innovative therapeutic approaches for diabetes prevention and care.

Indexed as

adipokinesadipose tissueinflammationtype 2 diabetesvisceral fat

Identifiers

PMID29264519
PMCPMC5686652
OpenAlexW2605479124

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.